Modern Staging and Utility of PET Imaging in Esophageal Cancer Management

Authors: Kwang-Yu Chang MDa, Jang-Yang Chang MDa, Joseph Chao MDa, and Yun Yen MD, PhDa
View More View Less
  • a From the National Institute of Cancer Research, National Health Research Institute, and Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan; and Department of Medical Oncology, City of Hope National Medical Center, Duarte, California.

Esophageal cancer is the eighth most common cancer worldwide, and one of the most fatal diseases despite modern medical treatment. Because correct staging and surveillance of neoadjuvant therapy for esophageal cancer is mandatory for further treatment planning, choosing a modern imaging system is important. The development of 18F-fluorodeoxyglucose positron emission tomography (18F-FDG-PET) has provided alternate means of tumor detection distinct from more conventional methods. This modality has extraordinary performance in detecting locoregional lymph node involvement and distant metastatic disease, and has been introduced as a powerful tool in many guidelines. However, some factors still lead to false-negative or -positive results, raising questions of its accuracy. This article discusses the clinical efficacy of PET in staging and surveillance of neoadjuvant therapy in esophageal cancer, comparing its accuracy with conventional imaging modalities.

Correspondence: Yun Yen, MD, PhD, Department of Medical Oncology, City of Hope National Medical Center, 1500 East Duarte Road, Duarte, CA 91010. E-mail: YYen@coh.org
  • 1.

    Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 2006;24:21372150.

    • Search Google Scholar
    • Export Citation
  • 2.

    Jemal A, Siegel R, Ward E et al.. Cancer statistics, 2008. CA Cancer J Clin 2008;58:7196.

  • 3.

    Koshy M, Esiashvilli N, Landry JC et al.. Multiple management modalities in esophageal cancer: combined modality management approaches. Oncologist 2004;9:147159.

    • Search Google Scholar
    • Export Citation
  • 4.

    Rosch T. Endosonographic staging of esophageal cancer: a review of literature results. Gastrointest Endosc Clin N Am 1995;5:537547.

  • 5.

    Chandawarkar RY, Kakegawa T, Fujita H et al.. Endosonography for preoperative staging of specific nodal groups associated with esophageal cancer. World J Surg 1996;20:700702.

    • Search Google Scholar
    • Export Citation
  • 6.

    Mallery S, Van Dam J. EUS in the evaluation of esophageal carcinoma. Gastrointest Endosc 2000;52(6 Suppl):S611.

  • 7.

    Fletcher JW, Djulbegovic B, Soares HP et al.. Recommendations on the use of 18F-FDG PET in oncology. J Nucl Med 2008;49:480508.

  • 8.

    Gallagher BM, Fowler JS, Gutterson NI et al.. Metabolic trapping as a principle of radiopharmaceutical design: some factors responsible for the biodistribution of [18F] 2-deoxy-2-fluoro-D-glucose. J Nucl Med 1978;19:11541161.

    • Search Google Scholar
    • Export Citation
  • 9.

    Pfau PR, Perlman SB, Stanko P et al.. The role and clinical value of EUS in a multimodality esophageal carcinoma staging program with CT and positron emission tomography. Gastrointest Endosc 2007;65:377384.

    • Search Google Scholar
    • Export Citation
  • 10.

    Flamen P, Lerut A, Van Cutsem E et al.. Utility of positron emission tomography for the staging of patients with potentially operable esophageal carcinoma. J Clin Oncol 2000;18:32023210.

    • Search Google Scholar
    • Export Citation
  • 11.

    Lerut T, Flamen P, Ectors N et al.. Histopathologic validation of lymph node staging with FDG-PET scan in cancer of the esophagus and gastroesophageal junction: a prospective study based on primary surgery with extensive lymphadenectomy. Ann Surg 2000;232:743752.

    • Search Google Scholar
    • Export Citation
  • 12.

    Lowe VJ, Booya F, Fletcher JG et al.. Comparison of positron emission tomography, computed tomography, and endoscopic ultrasound in the initial staging of patients with esophageal cancer. Mol Imaging Biol 2005;7:422430.

    • Search Google Scholar
    • Export Citation
  • 13.

    Luketich JD, Friedman DM, Weigel TL et al.. Evaluation of distant metastases in esophageal cancer: 100 consecutive positron emission tomography scans. Ann Thorac Surg 1999;68:11331136.

    • Search Google Scholar
    • Export Citation
  • 14.

    Sihvo EI, Rasanen JV, Knuuti MJ et al.. Adenocarcinoma of the esophagus and the esophagogastric junction: positron emission tomography improves staging and prediction of survival in distant but not in locoregional disease. J Gastrointest Surg 2004;8:988996.

    • Search Google Scholar
    • Export Citation
  • 15.

    Yoon YC, Lee KS, Shim YM et al.. Metastasis to regional lymph nodes in patients with esophageal squamous cell carcinoma: CT versus FDG PET for presurgical detection prospective study. Radiology 2003;227:764770.

    • Search Google Scholar
    • Export Citation
  • 16.

    Little SG, Rice TW, Bybel B et al.. Is FDG-PET indicated for superficial esophageal cancer? Eur J Cardiothorac Surg 2007;31:791796.

  • 17.

    Block MI, Patterson GA, Sundaresan RS et al.. Improvement in staging of esophageal cancer with the addition of positron emission tomography. Ann Thorac Surg 1997;64:770776.

    • Search Google Scholar
    • Export Citation
  • 18.

    Wren SM, Stijns P, Srinivas S. Positron emission tomography in the initial staging of esophageal cancer. Arch Surg 2002;137:10011006.

  • 19.

    Lardinois D, Weder W, Hany TF et al.. Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. N Engl J Med 2003;348:25002507.

    • Search Google Scholar
    • Export Citation
  • 20.

    van Westreenen HL, Westerterp M, Sloof GW et al.. Limited additional value of positron emission tomography in staging oesophageal cancer. Br J Surg 2007;94:15151520.

    • Search Google Scholar
    • Export Citation
  • 21.

    van Westreenen HL, Westerterp M, Bossuyt PM et al.. Systematic review of the staging performance of 18F-fluorodeoxyglucose positron emission tomography in esophageal cancer. J Clin Oncol 2004;22:38053812.

    • Search Google Scholar
    • Export Citation
  • 22.

    van Vliet EP, Heijenbrok-Kal MH, Hunink MG et al.. Staging investigations for oesophageal cancer: a meta-analysis. Br J Cancer 2008;98:547557.

  • 23.

    Urschel JD, Vasan H, Blewett CJ. A meta-analysis of randomized controlled trials that compared neoadjuvant chemotherapy and surgery to surgery alone for resectable esophageal cancer. Am J Surg 2002;183:274279.

    • Search Google Scholar
    • Export Citation
  • 24.

    Ancona E, Ruol A, Santi S et al.. Only pathologic complete response to neoadjuvant chemotherapy improves significantly the long term survival of patients with resectable esophageal squamous cell carcinoma: final report of a randomized, controlled trial of preoperative chemotherapy versus surgery alone. Cancer 2001;91:21652174.

    • Search Google Scholar
    • Export Citation
  • 25.

    Rohatgi PR, Swisher SG, Correa AM et al.. Failure patterns correlate with the proportion of residual carcinoma after preoperative chemoradiotherapy for carcinoma of the esophagus. Cancer 2005;104:13491355.

    • Search Google Scholar
    • Export Citation
  • 26.

    Beseth BD, Bedford R, Isacoff WH et al.. Endoscopic ultrasound does not accurately assess pathologic stage of esophageal cancer after neoadjuvant chemoradiotherapy. Am Surg 2000;66:827831.

    • Search Google Scholar
    • Export Citation
  • 27.

    Jones DR, Parker LA Jr, Detterbeck FC, Egan TM. Inadequacy of computed tomography in assessing patients with esophageal carcinoma after induction chemoradiotherapy. Cancer 1999;85:10261032.

    • Search Google Scholar
    • Export Citation
  • 28.

    Swisher SG, Maish M, Erasmus JJ et al.. Utility of PET, CT, and EUS to identify pathologic responders in esophageal cancer. Ann Thorac Surg 2004;78:11521160.

    • Search Google Scholar
    • Export Citation
  • 29.

    Brücher BL, Weber W, Bauer M et al.. Neoadjuvant therapy of esophageal squamous cell carcinoma: response evaluation by positron emission tomography. Ann Surg 2001;233:300309.

    • Search Google Scholar
    • Export Citation
  • 30.

    Flamen P, Van Cutsem E, Lerut A et al.. Positron emission tomography for assessment of the response to induction radiochemotherapy in locally advanced oesophageal cancer. Ann Oncol 2002;13:361368.

    • Search Google Scholar
    • Export Citation
  • 31.

    Mamede M, Abreu-E-Lima P, Oliva MR et al.. FDG-PET/CT tumor segmentation-derived indices of metabolic activity to assess response to neoadjuvant therapy and progression-free survival in esophageal cancer: correlation with histopathology results. Am J Clin Oncol 2007;30:377388.

    • Search Google Scholar
    • Export Citation
  • 32.

    Westerterp M, van Westreenen HL, Reitsma JB et al.. Esophageal cancer: CT, endoscopic US, and FDG PET for assessment of response to neoadjuvant therapy–systematic review. Radiology 2005;236:841851.

    • Search Google Scholar
    • Export Citation
  • 33.

    Brink I, Hentschel M, Bley TA et al.. Effects of neoadjuvant radiochemotherapy on 18F-FDG-PET in esophageal carcinoma. Eur J Surg Oncol 2004;30:544550.

    • Search Google Scholar
    • Export Citation
  • 34.

    Bruzzi JF, Swisher SG, Truong MT et al.. Detection of interval distant metastases: clinical utility of integrated CT-PET imaging in patients with esophageal carcinoma after neoadjuvant therapy. Cancer 2007;109:125134.

    • Search Google Scholar
    • Export Citation
  • 35.

    Downey RJ, Akhurst T, Ilson D et al.. Whole body 18FDG-PET and the response of esophageal cancer to induction therapy: results of a prospective trial. J Clin Oncol 2003;21:428432.

    • Search Google Scholar
    • Export Citation
  • 36.

    Port JL, Lee PC, Korst RJ et al.. Positron emission tomographic scanning predicts survival after induction chemotherapy for esophageal carcinoma. Ann Thorac Surg 2007;84:393400.

    • Search Google Scholar
    • Export Citation
  • 37.

    Westerterp M, Sloof GW, Hoekstra OS et al.. (18)FDG uptake in oesophageal adenocarcinoma: linking biology and outcome. J Cancer Res Clin Oncol 2008;134:227236.

    • Search Google Scholar
    • Export Citation
  • 38.

    Weber WA, Ott K, Becker K et al.. Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. J Clin Oncol 2001;19:30583065.

    • Search Google Scholar
    • Export Citation
  • 39.

    Ott K, Weber WA, Lordick F et al.. Metabolic imaging predicts response, survival, and recurrence in adenocarcinomas of the esophagogastric junction. J Clin Oncol 2006;24:46924698.

    • Search Google Scholar
    • Export Citation
  • 40.

    Lordick F, Ott K, Krause BJ et al.. PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial. Lancet Oncol 2007;8:797805.

    • Search Google Scholar
    • Export Citation
  • 41.

    Gillham CM, Lucey JA, Keogan M et al.. (18)FDG uptake during induction chemoradiation for oesophageal cancer fails to predict histomorphological tumour response. Br J Cancer 2006;95:11741179.

    • Search Google Scholar
    • Export Citation
  • 42.

    Wieder HA, Brucher BL, Zimmermann F et al.. Time course of tumor metabolic activity during chemoradiotherapy of esophageal squamous cell carcinoma and response to treatment. J Clin Oncol 2004;22:900908.

    • Search Google Scholar
    • Export Citation
  • 43.

    Song SY, Kim JH, Ryu JS et al.. FDG-PET in the prediction of pathologic response after neoadjuvant chemoradiotherapy in locally advanced, resectable esophageal cancer. Int J Radiat Oncol Biol Phys 2005:63:10531059.

    • Search Google Scholar
    • Export Citation
  • 44.

    Levine EA, Farmer MR, Clark P et al.. Predictive value of 18-fluorodeoxy-glucose-positron emission tomography (18F-FDG-PET) in the identification of responders to chemoradiation therapy for the treatment of locally advanced esophageal cancer. Ann Surg 2006;243:472478.

    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 148 64 7
PDF Downloads 129 72 7
EPUB Downloads 0 0 0